Impact of Annual Cardiovascular Screening Tests in Patients with Type 2 Diabetes Mellitus without Previous Histories of Cardiovascular Disease: Four-year Clinical Outcomes

Objective We previously reported that, among asymptomatic patients with type 2 diabetes mellitus (T2DM) without a history of cardiovascular disease (CVD), up to 19% of the patients with myocardial ischemia were detected by annual cardiovascular screening tests (ACVSTs). Thus, the present study asses...

Full description

Saved in:
Bibliographic Details
Published in:Internal Medicine 2021/09/01, Vol.60(17), pp.2725-2732
Main Authors: Antoku, Yoshibumi, Takemoto, Masao, Mito, Takahiro, Shiiyama, Ryuta, Otsuka-Morisaki, Hiroko, Tanaka, Atsushi, Maeda, Yasutaka, Tsuchihashi, Takuya
Format: Article
Language:English
Subjects:
all-cause mortality
Angiotensin
Cardiovascular disease
Cardiovascular diseases
cardiovascular events
cardiovascular screening test
Cholesterol
Clinical outcomes
Congestive heart failure
coronary artery disease
Diabetes
diabetes mellitus
Diabetes mellitus (non-insulin dependent)
heart failure
Internal medicine
Ischemia
Myocardial ischemia
Original
Patients
Renal function
Renin
Statins
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective We previously reported that, among asymptomatic patients with type 2 diabetes mellitus (T2DM) without a history of cardiovascular disease (CVD), up to 19% of the patients with myocardial ischemia were detected by annual cardiovascular screening tests (ACVSTs). Thus, the present study assessed the long-term clinical outcomes of ACVSTs in those patients. Methods Six hundred and fifty-seven outpatients with T2DM who received ACVSTs at least once or not at all from April 2014 to March 2018 were defined as the S and NS groups, respectively. The data were compared between these two groups. Results This study revealed that, among outpatients with T2DM in our hospital over those four years, with the increasing frequency of receiving ACVSTs, 1) the frequency of the internal use of statins, anti-platelets, and renin-angiotensin system inhibitors, which are well-known as medications for preventing CVD, significantly increased; 2) low-density lipoprotein-cholesterol and triglyceride levels significantly improved; 3) levels of highly sensitive C-protein, a strong predictors of CVD, were significantly suppressed; 4) the progression of renal dysfunction was significantly suppressed; 5) the cumulative of four-point major adverse cardiovascular events and admissions due to heart failure significantly decreased; and 6) the cumulative of all-cause mortality was significantly suppressed. Conclusions Given the above, it may be important to continue ACVSTs in outpatients with T2DM without a history of CVD for several years.
ISSN:0918-2918
1349-7235
DOI:10.2169/internalmedicine.6893-20